CTOs on the Move

Emergent BioSolutions

www.emergentbiosolutions.com

 
Emergent BioSolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Matthew Burry
Sr. Director of Information Security Profile
Chii-Ren Tsai
Director, Global Information Security Architecture and Engineering Profile
Eberechi Ugwo-Amole
Director - Information Security and Risk Profile

Jobs

VP, Chief Information Security Officer

Emergent BioSolutions Remote
Details here:
https://careers.emergentbiosolutions.com/job/Gaithersburg-Vice-President%2C-Chief-Information-Security-Officer-Remote-MD-20879/1200080000/?feedId=306800&utm_source=Indeed&utm_campaign=EmergentBio_Indeed&jobPipeline=Indeed

Funding

Emergent BioSolutions raised $20M on 09/25/2019
Emergent BioSolutions raised $14.5M on 04/03/2020

Similar Companies

Summit Therapeutics

We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.

Carbon Sciences, Inc

Carbon Sciences Inc. is developing a breakthrough technology to transform carbon dioxide (CO2) emissions into the basic fuel building blocks required to produce gasoline, diesel fuel, jet fuel and other portable fuels.

Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 and top-line data for the full 12-month treatment period are anticipated in the second quarter of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.

ZyStor Therapeutics

ZyStor Therapeutics is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tropical Looks Day Spa

Tropical Looks Day Spa is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.